VTAMA® (tapinarof) Cream 1% for Psoriasis

Phase-Based Progress Estimates
PsoriasisVTAMA® (tapinarof) Cream 1% - Drug
All Sexes
What conditions do you have?

Study Summary

This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with intertriginous psoriasis

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: from Baseline to Week 12

Week 12
Percentage of participants who achieve an intertriginous PGA (iPGA) score of clear (0) or almost clear (1) with a ≥ 2-grade improvement
Time to achieve an iPGA score of 0 or 1 with a ≥ 2 grade improvement

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

VTAMA® (tapinarof) Cream 1%
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: VTAMA® (tapinarof) Cream 1% · No Placebo Group · Phase 4

VTAMA® (tapinarof) Cream 1%
Experimental Group · 1 Intervention: VTAMA® (tapinarof) Cream 1% · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from baseline to week 12

Who is running the clinical trial?

Dermavant Sciences, Inc.Lead Sponsor
3 Previous Clinical Trials
1,097 Total Patients Enrolled
1 Trials studying Psoriasis
100 Patients Enrolled for Psoriasis
Victoria ButnersStudy DirectorDermavant Sciences, Inc.
3 Previous Clinical Trials
1,788 Total Patients Enrolled
3 Trials studying Psoriasis
1,788 Patients Enrolled for Psoriasis

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must have a negative pregnancy test on the first day.
You are able to provide written permission for participation.
Female participants who are of reproductive age and engaging in activities that could result in pregnancy agree to adhere to the specified contraceptive requirements during the research.
You are 18 or older, as of the date you agreed to the informed consent.
You have a clinical diagnosis of plaque psoriasis with lesion(s) in intertriginous areas and your condition has been stable for 3 or more months prior to the study.
You have a mild, moderate, or severe iPGA score at screening and baseline.

Who else is applying?

What state do they live in?
What portion of applicants met pre-screening criteria?
Met criteria100.0%
Why did patients apply to this trial?
  • "To try something that could possibly help clear up my skin."
How many prior treatments have patients received?